相关实验视频

Updated: Jul 4, 2025

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

通过人工智能驱动的发现,在癌症中抑制CTLA-4的小分子

Navid Sobhani^1,2, Dana Rae Tardiel-Cyril¹, Dafei Chai¹

¹Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.

|February 5, 2024

概括

人工智能发现了针对细胞毒性T淋巴细胞相关蛋白4 (CTLA-4) 的新型小分子,用于癌症免疫治疗. 这些化合物有效地破坏了CTLA-4/CD80相互作用,在临床前癌症模型中显示出前景.

科学领域:

免疫学免疫学免疫学
计算化学计算化学
药物发现药物发现药物发现

背景情况:

检查点抑制剂已经改变了癌症免疫疗法,但也有局限性.
针对CTLA-4的单克隆抗体可以导致严重的免疫相关不良事件.
现有的小分子向CD80,而不是CTLA-4,限制了直接的治疗干预.

研究的目的:

通过使用人工智能驱动的虚拟查来识别CTLA-4/CD80相互作用的新型小分子抑制剂.
为了验证和优化这些抑制剂的潜在的癌症治疗.

主要方法:

通过人工智能驱动的虚拟选大约1000万种化合物,以识别CTLA-4向剂.
在体外和体内验证使用生物化学,生物物理,免疫学和动物测试.
优化化合物以获得CTLA-4/CD80相互作用的强抑制剂.

主要成果:

人工智能选成功识别了针对CTLA-4的验证命中分子.
优化的化合物在微分子度下抑制CTLA-4/CD80相互作用,而不会降解CTLA-4.
几种化合物在临床前癌症模型中显示出预防和治疗效果.

结论:

基于人工智能的框架对于设计针对免疫检查点的小分子是有效的.
这些已识别的化合物显示出开发新型癌症免疫疗法的潜力.
这种方法为克服当前检查点抑制剂疗法的局限性提供了一个有希望的策略.

更多相关视频

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...